Nationwide Fund Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Nationwide Fund Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,622	Closed	-$246K	–	2356
2017 Q3	$246K	Hold	4,622	–	–	﹤0.01%	2541
2017 Q2	$263K	Buy	4,622 +513	+12%	+$25.7K	﹤0.01%	2508
2017 Q1	$221K	Sell	4,109 -242	-6%	-$13.7K	﹤0.01%	2542
2016 Q4	$248K	Sell	4,351 -234	-5%	-$14.2K	﹤0.01%	2510
2016 Q3	$285K	Hold	4,585	–	–	﹤0.01%	2452
2016 Q2	$259K	Buy	4,585 +3,502	+323%	+$213K	﹤0.01%	2489
2016 Q1	$69K	Hold	1,083	–	–	﹤0.01%	2924
2015 Q4	$152K	Hold	1,083	–	–	﹤0.01%	2674
2015 Q3	$105K	Hold	1,083	–	–	﹤0.01%	2881
2015 Q2	$164K	Buy	+1,083	New	+$179K	﹤0.01%	2804

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nationwide Fund Advisors's KDNY Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017, closing a stake of 4,622 shares — an estimated $246K sold.

Nationwide Fund Advisors first reported a position in KDNY in Q2 2015 and held it in 10 quarters. The position peaked at $285K in Q3 2016. 94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

Nationwide Fund Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 4,622 Chinook Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $246K.
Nationwide Fund Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 10 quarters.
Nationwide Fund Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $285K in Q3 2016.
94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.